Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 106

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 106
---
 intranasal administration route, the Company plans to engage in early regulatory consultations with the FDA (e.g., pre-IND
meeting) to confirm study design and development plans. The Company may also explore opportunities for expedited pathways (e.g., Fast
Track designation) depending on the selected viral target and emerging public health needs.

At present, all vaccine development activities
remain temporarily suspended until final review of the preclinical results is completed. The Company’s continued investment will
depend on the scientific and regulatory merit of the final data package.

Yissum Research and License Agreements

Our rights to the foregoing are based on research
and license agreement with Yissum, the tech transfer company of the Hebrew University in Jerusalem. Below is a summary of the principal
terms of these agreements.

On November 24, 2022, LipoVation entered into
the Yissum Agreements, which were subsequently amended. Pursuant to the Yissum License Agreements, Yissum granted LipoVation an exclusive,
worldwide, sublicensable license to develop, have developed, manufacture, have manufactured, use, market, distribute, export, import
and/or sell products and/or processes that comprise, contain or incorporate certain technology relating to the Nanoparticles-based liposomal
therapeutics, including the above noted patents (the “Licensed Patents”). Under the terms of the Yissum Agreements, Yissum
retains the ownership of the Licensed Technology (as such term is defined therein). All rights in the results of the activities carried
out by LipoVation or third parties in the development of these products shall be solely owned by LipoVation (unless an employee of the
Hebrew University of Jerusalem or each of its branches is an inventor of any of the patents claiming such results, in which case they
shall be owned jointly by Yissum and LipoVation). LipoVation m has the right to grant sub-licenses to third parties in accordance with
the terms set forth in the Yissum Agreements.

<div align='center'>65</div>

Notwithstanding granting LipoVation the exclusive
license, Yissum and the Hebrew University of Jerusalem retained the right to make non-commercial, academic use of the technology at the
Hebrew University, including academic research sponsored by third parties that does not conflict or interfere with the license. In addition,
Yissum may grant licenses to third party academic or research institutions for non-commercial, academic research